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Bluetongue (BT) is a non-contagious disease of sheep and other domestic and wild 
ruminants caused by the bluetongue virus (BTV). Currently 26 serotypes of the virus have 
been identified. In South Africa, 22 serotypes have been identified and BT is controlled 
mainly by annual vaccinations using a freeze-dried live attenuated polyvalent BTV vaccine. 
The vaccine is constituted of 15 BTV serotypes divided into three separate bottles and the 
aim is to develop a vaccine using fewer serotypes without compromising the immunity 
against the disease. This study is based on previously reported cross-neutralisation of specific 
BTV serotypes in in vitro studies. Bluetongue virus serotype 4 was selected for this trial and 
was tested for cross-protection against serotype 4 (control), 1 (unrelated serotype), 9, 10 and 
11 in sheep using the serum neutralisation test. The purpose of the study was to determine 
possible cross-protection of different serotypes in sheep. Of those vaccinated with BTV-4 
and challenged with BTV-1, which is not directly related to BTV-4, 20% were completely 
protected and 80% showed clinical signs, but the reaction was not as severe as amongst the 
unvaccinated animals. In the group challenged with BTV-10, some showed good protection 
and some became very sick. Those challenged with BTV-9 and BTV-11 had good protection. 
The results showed that BTV-4 does not only elicit a specific immune response but can also 
protect against other serotypes. 
Introduction
Bluetongue (BT) is an insect-borne viral disease of ruminants caused by the bluetongue virus (BTV). 
The disease has a major impact on the economy and animal welfare in affected countries and has 
the ability to spread to new geographical areas where naive animal populations are at risk. BTV 
has a wide host range, mostly affecting sheep, but also goats, cattle and some wild ruminants. 
Twenty-six serotypes are known of which 22, except BTV-20, BTV-21, BTV-25 and BTV-26, are 
endemic and co-circulate in southern Africa (Gerdes 2004; Mertens et al. 2007). Serological cross-
neutralisation amongst BTV serotypes within specific groups using the serum neutralisation test 
(SNT) is well described (Erasmus 1990) (Figure 1). However, only a few studies exist where sheep 
were used to determine cross-protection. Jeggo (1986) inoculated sheep with BTV-4 and challenged 
them at various intervals with BTV-3, showing protection only for 14 days after the first inoculation. 
Simultaneous infection with three BTV serotypes also resulted in the replication of only two 
(Jeggo, Wardley & Taylor 1984). Using a recombinant vaccine, Perez de Diego et al. (2011) and 
Calvo-Pinilla et al. (2012) showed that BTV protection is serotype-specific and that homologous 
protection involves antibodies and a T-cell response, whilst heterologous protection is supported 
by a T-cell response directed to the NS1 encoding gene (Schwartz-Cornil et al. 2008).
The most effective method of controlling BT in endemic areas like South Africa is by prophylactic 
vaccination or protecting the animals from being bitten by the midge vector (Ilango 2006). Live 
attenuated vaccines (LAVs) and inactivated vaccines are mainly used in southern Africa and 
Europe, respectively (Savini et al. 2008). The LAV is constituted of 15 BTV serotypes divided into 
three separate bottles and the challenge is to shorten the time between the first vaccination and 
the time when the animal is fully protected (up to 9 weeks). During this lengthy period, animals 
are at risk of developing the disease due to infection with the serotypes which they have not yet 
been inoculated against (Dungu, Gerdes & Smit 2004). The purpose of the study was to determine 
whether the number of serotypes in the vaccine can be reduced without affecting efficacy, thus 
shortening the time taken for the development of complete immunity after vaccination of animals.
Materials and methods
BTV-specific antibody-free (BTV-specific ELISA negative) indigenous mutton-merino sheep 
were used. BTV serotype 4 at a titre of 4.2 x 106 log10 TCID50/mL was used as the vaccine and 
the standard Onderstepoort Biological Products challenge material for BTV-4 (control), BTV-1 
(unrelated virus), BTV-9, BTV-10 and BTV-11 (related to BTV-4) were used as challenge material. 
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Serum was collected on day 0 and sheep were then grouped 
into vaccinated and unvaccinated as follows: 27 sheep were 
inoculated subcutaneously with 2 mL live attenuated BTV-4 
vaccine and five were left unvaccinated as negative controls. 
The animals were monitored for clinical reactions twice 
daily for 14 days and were bled weekly to assess antibody 
reaction. On day 28, four groups of six animals each – five 
vaccinated animals and one unvaccinated animal – were 
challenged intravenously with different serotypes, namely 
BTV-1, BTV-9, BTV-10 and BTV-11. Two vaccinated animals 
were challenged with BTV-4. After vaccination and challenge 
the animals were monitored for BT-related clinical signs 
of fever (normal rectal temperature ranges between 37 °C 
and 40 °C), depression, dyspnoea, haemorrhages and for 
all clinical signs associated with endothelial cell damage. 
The BTV-4 cross-protection and degree of clinical reaction 
post-challenge was measured using percentage protection 
index (PPI) values with a cut-off value of 55% (Huismans 
et al. 1987). A PPI above 55% with no overt clinical signs was 
regarded as protective. The clinical reaction of the animals 
post-challenge was monitored serologically using SNT with 
a cut-off value of 1:16. 
Results
Significant clinical signs were observed in animals challenged 
with BTV-1 with low neutralising antibodies (below 1:16), 
which indicated the lack of protective antibodies. Animals 
challenged with BTV-9 showed no clinical signs and 
protective neutralising antibodies against the virus were 
present. Animals challenged with BTV-10 had neutralising 
antibody titres above 1:16, but some animals showed 
overt clinical signs. This indicates that BTV-4 neutralising 
antibodies were not sufficient to provide protection to animals 
against BTV-10. Some animals did not show any clinical signs 
although SNT titres were above the cut-off value (BTV-10). 
These animals could have been infected subclinically 
(Sperlova & Zendulkova 2011). The animals challenged 
with BTV-11 had a 100% PPI value but the SNT results were 
below the cut-off value of 1:16. A possible explanation is 
that the cell-mediated immune response, specifically T-cells 
directed to the NS1 non-structural and inner core proteins, 
played a role in the protection of the animals (Schwartz-
Cornil et al. 2008). Therefore, BTV-4 vaccine should not be 
used as the primary vaccine for protection against BTV-1 and 
BTV-10; however, animals were protected against BTV-9 
and BTV-11 by BTV-4 neutralising antibodies. According 
to Figure 1, BTV-1 is only distantly related to BTV-4, which 
might be the reason why there was poor cross-protection. In 
vivo vaccine studies should include different combinations of 
serotypes and investigate both humoral and cellular immune 
responses together with clinical signs. The immunogenicity 
of the different BTV serotypes differ; the different titres used 
in a vaccine and the ability to replicate well in host cells also 
play a role in eliciting a strong humoral immune response 
(Dungu et al. 2004; Modumo & Venter 2012). 
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in ruminants, pp. 227–237, Elsevier Science Publishers, Amsterdam
FIGURE 1: Serological cross-neutralisation of bluetongue virus serotypes. 
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